ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
17 announcements with these filters
Venmax Drugs and Pharmaceuticals held its 37th Annual General Meeting on September 26, 2026. Shareholders considered the financial statements and various directorship appointments.
Venmax Drugs and Pharmaceuticals Limited announced an NCLT-convened meeting of equity shareholders on October 24, 2026, to consider the proposed merger with Hatri Pharma Private Limited.
NCLT Hyderabad directed Venmax to convene a shareholder meeting on 24 Oct 2026 for the amalgamation of Hatri Pharma into Venmax. The order also dispensed with meetings of Hatri Pharma's shareholders and creditors.
Venmax Drugs and Pharmaceuticals Limited has submitted its Annual Report for the Financial Year 2025-26, including the Notice for its 37th Annual General Meeting.
Venmax Drugs held a board meeting to approve the Directors' Report, AGM date, and appoint/regularize key directors. The meeting outcomes were disclosed under Regulation 30.
Venmax Drugs & Pharmaceuticals scheduled a board meeting for August 31, 2026. The board will approve the 37th Annual Report and fix details for the Annual General Meeting.
Venmax Drugs and Pharmaceuticals Limited filed a statement confirming no deviation or variation in the utilization of proceeds from its previous preferential issue.
Venmax Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹2.5 Cr (+108.3% YoY) and net profit of ₹0.1 Cr for Q1 FY27.
Venmax Drugs and Pharmaceuticals has scheduled a board meeting for August 7, 2026, to consider quarterly financial results and forfeiture of partly paid-up share warrants.
Venmax Drugs and Pharmaceuticals Ltd allotted 7,53,334 equity shares upon conversion of warrants at Rs. 20 per share. This conversion increases the company's equity capital.
Venmax Drugs and Pharmaceuticals allotted 21,47,665 equity shares upon warrant conversion for a consideration of Rs. 3.22 Crore. This increases the company's paid-up share capital.
Venmax Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹3.9 Cr (+1200.0% YoY) and net profit of ₹0.1 Cr (-87.5% YoY) for Q4 FY26.
Venmax Drugs and Pharmaceuticals reported annual revenue of ₹8.19 Crore for FY2026. The results show significant growth compared to the previous financial year.
Venmax Drugs and Pharmaceuticals Ltd has scheduled a Board Meeting on May 14, 2026. The board will consider and approve the audited financial results for the quarter and year ended March 31, 2026. The company's trading window remains closed until May 16, 2026.
Venmax Drugs and Pharmaceuticals Ltd (BSE: 531015) confirmed it does not meet the SEBI 'Large Corporate' criteria as of March 31, 2026. The company reported zero outstanding borrowings and a nil credit rating for the period. This routine regulatory disclosure clarifies the company's borrowing framework status for investors.
Venmax Drugs and Pharmaceuticals Limited informed BSE that it is exempt from submitting the Annual Secretarial Compliance Report for the year ended March 31, 2026. The exemption applies as the company's paid-up capital and net worth remain below the regulatory thresholds specified under Regulation 15(2) of SEBI (LODR) Regulations 2015.
Venmax Drugs and Pharmaceuticals Ltd promoter, Venkat Narender Nuka, submitted the annual SEBI (SAST) declaration for FY 2025-26. The promoter confirmed holding 9,26,775 shares and stated that no encumbrances or pledges were made on these shares during the period.